Document Detail


Mechanical vs intrinsic components in the improvement of brachial arterial compliance. Comparison of the effects of atenolol versus ramipril in hypertensive patients.
MedLine Citation:
PMID:  11721319     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The aim of this study was to compare the mechanical and intrinsic effects of an angiotensin converting enzyme inhibitor, vs a beta-blocker, on brachial arterial compliance. In a double blind study, 34 essential hypertensive patients were treated for 3 months with either ramipril 2.5-5.0 mg daily (n = 17, age 57 +/- 7 y, 11 males) or atenolol 50-100 mg daily (n = 17, age 53 +/- 8 y, 11 males). Blood pressure (BP), brachial artery diameter (D), brachial-radial pulse wave velocity (PWV) and effective compliance (Ceff), were measured before and at the end of the study. Isobaric evaluation (Ciso) was performed in the entire population studied at an average mean BP of 110 mmHg. Ramipril significantly reduced BP from 155 +/- 16/94 +/- 6 mmHg to 140 +/- 15/85 +/- 7 mmHg (p < 0.001) without affecting heart rate (HR; 74 +/- 10 vs. 75 +/- 12 bpm). In addition, it significantly improved both PWV (18%; p < 0.001) and arterial compliance (45%; p < 0.001), from which 35% was related to a pressure independent effect (p < 0.01). Atenolol also induced a reduction in both BP (159 +/- 17/96 +/- 10 to 133 +/- 13/81 +/- 8 mmHg; p < 0.001) and HR (76 +/- 10 to 57 +/- 7 bpm; p < 0.001). In a similar way, PWV (11%; p < 0.05) and Ceff (30%; p < 0.05) were significantly improved without significant change in Ciso. This suggests that blood pressure reduction was responsible for compliance improvement. In conclusion, it is suggested that atenolol induces only hemodynamic changes, mediated mainly by BP reduction. In contrast, the improved brachial buffering function observed after ramipril involves not only hemodynamic changes, but also changes mediated by other mechanisms, such as modification of wall structures.
Authors:
R L Armentano; S Graf; A J Ramírez; J D Espinosa; L Brandani; H Baglivo; R Sánchez
Related Documents :
20198199 - Effects of nebivolol versus bisoprolol on endothelial function in hypertensive patients.
7755939 - Effects of intensified blood-pressure reduction on renal function and albumin excretion...
14700519 - Hypertension in women.
10078889 - Blood pressure behavior in the nursing home: implications for diagnosis and treatment o...
20148909 - Does leptin predict incident hypertension in older adults?
2054279 - Interaction of indomethacin and sulindac with labetalol.
17201729 - Effect of bay 41-2272 in the pulmonary hypertension induced by heparin-protamine comple...
15812259 - A survey of validated automated home blood pressure monitors available for the internet...
24012989 - Swimmers can train in hypoxia at sea level through voluntary hypoventilation.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Medicina     Volume:  61     ISSN:  0025-7680     ISO Abbreviation:  Medicina (B Aires)     Publication Date:  2001  
Date Detail:
Created Date:  2001-11-27     Completed Date:  2002-01-22     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0204271     Medline TA:  Medicina (B Aires)     Country:  Argentina    
Other Details:
Languages:  eng     Pagination:  535-40     Citation Subset:  IM    
Affiliation:
Proyecto Dinámica del Sistema Arterial, Universidad Favaloro, Buenos Aires, Argentina. armen@favaloro.edu.ar
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / pharmacology,  therapeutic use
Angiotensin-Converting Enzyme Inhibitors / pharmacology,  therapeutic use
Antihypertensive Agents / pharmacology*,  therapeutic use
Atenolol / pharmacology*
Brachial Artery / drug effects*,  physiopathology
Compliance
Double-Blind Method
Female
Hemodynamics / drug effects
Humans
Hypertension / drug therapy*,  physiopathology
Male
Middle Aged
Ramipril / pharmacology*
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 29122-68-7/Atenolol; 87333-19-5/Ramipril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Functional respiratory evaluation in patients with high traumatic spinal injury
Next Document:  Asymptomatic Chagas disease. Electrocardiographic and echocardiographic findings